Multimodal Cure of Cancer

Translational T-cell therapies for solid tumorsPrasad Adusumilli, MD; Christopher Klebanoff, MD; Katharine Hsu, MD, PhD; David Scheinberg, MD, PhD
Curative therapy for leukemia through blockade of aberrant transcription and translationScott Armstrong, MD, PhD; Omar Abdel-Wahab, MD; Alex Kentsis, MD, PhD; Michael Kharas, PhD; Ross Levine, MD; Yueming Li, PhD
Innovative approaches to translating CAR T cell therapies to solid tumorsRenier Brentjens, MD, PhD; Prasad Adusumilli, MD; Christopher Klebanoff, MD; Michel Sadelain, MD, PhD; David Scheinberg, MD, PhD; Susan Slovin, MD
Strategies to harness cancer cell stress for treatment and diagnosisGabriela Chiosis, PhD; Adriana Corben, MD; Mark Dunphy, DO; Katharine Hsu, MD, PhD; Xuejun Jiang, PhD; Shanu Modi, MD; Larry Norton, MD; Nagavarakishore Pillarsetty, PhD; Derek Tan, PhD
A nanoscale therapeutic platform to target the solid tumor microenvironmentDaniel Heller, PhD; Adriana Haimovitz-Friedman, PhD; John Humm, PhD; Charles Rudin, MD, PhD; Charles Sawyers, MD; David Spriggs, MD
Curing relapsed refractory myeloma with combined immune-therapiesSergio Giralt, MD; Sham Mailankody, MD; Jonathan Peled, MD, PhD; David Chung, MD; Kazunori Murata, PhD
Toward the cure of adult acute lymphocytic leukemia: A personalized, genetic and epigenetic, chemo-immunotherapeutic approachJoseph Jurcic, MD; Renier Brentjens, MD, PhD; Cyrus Hedvat, MD, PhD; Ross Levine, MD; Peter Maslak, MD; Hans Guido Wendel, MD; Scott Armstrong, MD, PhD; Michael Kharas, PhD; David Scheinberg, MD, PhD
Targeted immunotherapeutic approaches to cure multiple myelomaGuenther Koehne, MD, PhD; David Chung, MD, PhD; C. Ola Landgren, MD, PhD; Alexander Lesokhin, MD
Multi-modality treatment of pancreatic ductal adenocarcinoma (PDAC)Jason Lewis, PhD; Peter Allen, MD; Jan Grimm, PhD; Christine Iacobuzio-Donahue, MD, PhD; Kayvan Keshari, PhD; Steven Leach, MD; Thomas Reiner, PhD
Developing curative therapies for BRAF and NRAS mutant tumorsNeal Rosen, MD, PhD; David Solit, MD
Changing the natural history of metastatic melanoma with multimodality therapyNeal Rosen, MD; Paul Chapman, MD; David Solit, MD; Scott Lowe, PhD; Jedd Wolchok, MD, PhD
Development of therapeutic strategies that change the natural history of tumors with mutant RASNeal Rosen, MD, PhD; Scott Lowe, PhD; David Solit, MD; Barry Taylor, PhD; Jedd Wolchok, MD, PhD
Towards a cure for prostate cancerCharles Sawyers, MD; Jason Lewis, PhD; Dana Rathkopf, MD; Michael Zelefsky,MD
Innovations in the structures, functions and targets of monoclonal antibody-based drugs for cancerDavid Scheinberg, MD, PhD; Renier Brentjens, MD, PhD; Steven Larson, MD; Hans-Guido Wendel, MD
Curing ovarian cancer through early detection and personalized treatmentDavid Spriggs, MD; Carol Aghajanian, MD; Douglas Levine, MD; Paul Sabbatini, MD

Multidisciplinary Team Research

Quillaja saponin adjuvants in carbohydrate conjugate cancer vaccinesDavid Gin, PhD; Adam Boruchov, MD; Paul Chapman, MD; Govind Ragupathi, PhD and Jim Young, MD
Cellular target discovery and therapeutic agents — Proteases as targets for cancer therapyYueming Li, PhD; David Scheinberg, MD, PhD; Xuejun Jiang, PhD and Johanna Joyce, PhD
Non-invasive imaging and monitoring of tumor hypoxiaClifton Ling, PhD; Jason Koutcher, MD, PhD; John Humm, PhD; Pat Zanzonico, PhD; Joseph O’Donoghue, PhD; and Ronald Finn, PhD
Development of active and adoptive immunotherapy of ovarian cancer targeting MUC16 and WT1Philip Livingston, MD and Richard O’Reilly, MD
Development of rational strategies for anti-cancer therapy based on inhibition of signaling through the Ras and PI3kinase signaling pathways — Combined inhibition of Raf/MEK/MAPK and PI3K/AKT signaling for the treatment of cancerNeal Rosen, MD, PhD; PhD; Charles Sawyers, MD; David Solit, MD; and David Spriggs, MD
Targeting tumors with genetically enhanced T lymphocytesMichel Sadelain, MD, PhD; Prasad Adusumilli, MD; Renier Brentjens, MD, PhD; Vladimir Ponomarev, MD, PhD; Isabelle Riviere, PhD; Susan Slovin, MD, PhD
Functional and advanced anatomic techniques for response assessment in solid tumorsLawrence Schwartz, MD and Robert Motzer, MD
An integrated multidisciplinary approach to developing new treatments for advanced prostate cancerDerek Tan, PhD; Gabriela Chiosis, PhD; Yueming Li, PhD; Neal Rosen, MD, PhD and Howard Scher, MD
Identification of cell cycle related kinase inhibitors for cancer therapyArchie Tse, MD, PhD and David Spriggs, MD
Immunotherapy of cancer: Development of cancer vaccines, adoptive cellular therapies, immune modulation and combination immunotherapiesMarcel van den Brink, MD, PhD; Ronald Blasberg, MD; Bo Dupont, MD, DSc; Alan Houghton, MD; Robert Jenq, MD; Steve Larson, MD; Jedd Wolchok, MD, PhD

Clinical Investigations

A phase I trial of malignant pleural mesothelioma treated with autologous T cells genetically targeted to the cancer cellPrasad Adusumilli, MD
A Phase 1a/1b Trial to Assess Safety and Bioactivity of Intrathecal Deferoxamine in Patients with Leptomeningeal Metastases from Non Small Cell Lung CancerAdrienne Boire, MD, PhD
Experimental Therapeutics Clinical Treatment UnitRichard Carvajal, MD
Vaccination of pancreatic cancer patients against mutated K-rasPaul Chapman, MD
Biologic correlates in a phase I/II study of humanized 3F8 bispecific antibody (hu3F8-BsAb) in patients with relapsed/refractory neuroblastoma, osteosarcoma, and other GD2(+) solid tumorsNai-Kong Cheung, MD, PhD
Clinical translation of PU-H71, a small molecule Hsp90 inhibitorGabriela Chiosis, PhD
Langerhans-type dendritic cell vaccination as consolidation for multiple myeloma after autologous stem cell transplantationDavid Chung, MD, PhD
Circulating tumor cells in patients with metastatic prostate cancer: Development of predictive biomarkers for sensitivity to androgen receptor targeted treatment sensitivityDaniel Danila, MD and Howard Scher, MD
The Development of a Novel AML-directed CAR T Cell Capable of Bystander Tumor KillingAnthony Daniyan, MD
Preclinical and clinical evaluations of first-generation recombinant modified vaccinia virus Ankara (MQ710) for the treatment of anaplastic thyroid cancer and other solid tumorsLiang Deng, MD, PhD
Targeting Lewis Y in small cell lung cancer using the humanized monoclonal antibody, hu3S193Chaitanya Divgi, MD
Cardenolides as novel agents for the treatment of retinoblastomaHakim Djaballah, PhD and David Abramson, MD
Radioimmunotherapy, reduced-dose radiation therapy, and chemotherapy for medulloblastomaIra Dunkel, MD and Kim Kramer, MD
Iso-fludelone, a novel epothilone: First in human phase 1 trialMrinal Gounder, MD and Naiyer Rizvi, MD
Assessing the continual reassessment method as a phase I design by comparing it to the standard dose escalation schemeAlexia Iasonos, PhD
Pilot trial 89Zr-trastuzumab-PET as pharmacodynamic marker in patients with HER2-positive esophagogastric cancerYelena Janjigian, MD
Hyperpolarized pyruvate MR imaging of prostate cancerKayvan Keshari, PhD
Comparative analyses of WT1 expression and WT1 antigen-specific T-cell frequencies in patients with plasma cell leukemia following treatment with donor-derived Wilms tumor antigen-specific T lymphocyte infusionsGuenther Koehne, MD, PhD
Development of KSR phosphorothioate antisense oligonucleotides for phase I clinical trialRichard Kolesnick, MD
A phase I study of convection-enhanced delivery of 124I-8H9 for patients with non-progressive diffuse pontine gliomas previously treated with external beam radiation therapyKim Kramer, MD
Phase I study of intrathecal 131-I-8H9 for central nervous system and leptomeningeal malignanciesKim Kramer, MD
Pilot trial of a tetravalent KLH conjugate vaccine against small cell lung cancerLee Krug, MD
Targeting small cell lung cancer with an Ac-labeled antibody to the ganglioside GD2Lee Krug, MD
Phase I trial of a tetravalent vaccine with escalating doses of the immunological adjuvant QS-21, in combination with oral beta-glucan for high-risk neuroblastomaBrian Kushner, MD
A Phase I Dose Escalation Study of ESK1-Bispecific T-cell Engager (ESK-TCE) Antibody Targeting WT1 for the Treatment of Patients with Recurrent Ovarian CancersChrisann Kyi, MD
Clinical and molecular-metabolic phase II trial of perifosine for recurrent/progressive malignant gliomasAndrew Lassman, MD
Combination of targeted radiotherapy and anti-angiogenesis for resistant neuroblastomaShakeel Modak, MD
Lutetium-177 radiolabeled anti-prostate specific membrane antigen antibodies and its relationship to tumor-absorbed radiation doseMichael Morris, MD
Quantitative PET imaging with yttrium-86 radiolabeled humanized anti-prostate specific membrane antibody J591 for dosimetric evaluation of yttrium-90-huJ591 therapyMichael Morris, MD
Targeted radioimmunotherapy using Ley as a target in castrate metastatic prostate cancerMichael Morris, MD
Prostate specific membrane antigen vaccine in prostate cancerLuke Nordquist, MD
Preclinical and clinical development of 10-propargyl-10-deazaaminopterin (PDX) in relapsed or refractory aggressive non-Hodgkin’s lymphomasOwen O’Connor, MD, PhD
A phase I clinical trial of a new targeted therapy for the treatment of metastatic pancreatic cancerEileen O’Reilly, MD
Cytokine Secreting CAR T-Cell Therapy for Treatment of LeukemiaJae Park, MD
GM-CSF DNA vaccine in melanomaMiguel Perales, MD
Phase 1 study of humanized 3F8 monoclonal antibody (Hu3F8) when combined with interleukin-2 in patients with high-risk neuroblastoma and GD2-positive solid tumorsStephen Roberts, MD
Augmented PSMA CAR therapy for castrate-resistant, metastatic prostate cancerMichel Sadelain, MD, PhD and Susan Slovin, MD, PhD
Preparation of a peptide vaccine for chronic myelogenous leukemiaDavid Scheinberg, MD, PhD
Biomarker development in patients with metastatic prostate cancer: Assays for androgen receptor signaling pathway in circulating tumor cellsHoward Scher, MD
Therapeutic response assessment in clinical trials: Development of tools for precise quantitative image analysisLawrence Schwartz, MD
Synthesis of 150 grams of PDXFrancis Sirotnak, PhD
Phase I trial of mouse TRP-2 DNA vaccine for patients with melanomaJedd Wolchok, MD, PhD
Alemtuzumab treatment of steroid-refractory acute graft-versus-host diseaseJames Young, MD

Drug Discovery and Development

Synthetic introns to enable mutation-dependent targeting of cancer cellsOmar Abdel-Wahab, MD
Imaging the efficacy of TRAIL-enhanced cancer immunotherapyPrasad Adusumilli, MD and Vladimir Ponomarev, MD, PhD
Small molecule degrader of HMGCS1 to harness the mevalonate pathway in cancerHeeseon An, PhD
Self-immolative tumor-targeted nanogeneratorsChristophe Antczak, PhD
New DPP8/9-binding ligands for the treatment of acute myeloid leukemiaDaniel Bachovchin, PhD
Induction of pyroptosis for cancer monocytic/macrophage lineageDaniel Bachovchin, PhD
Peptidase Inhibitors as New Cancer Immunotherapy AgentsDaniel Bachovchin, PhD
ID protein degradation as a therapeutic strategy for advanced cancersRobert Benezra, PhD; James Harding, MD
Tumor endothelial cell-specific inhibitor for Id-proteinsRobert Benezra, PhD
Over expression of asmase in endothelial stem cells by lentiviral vector deliveryNira Bloom, PhD
Expression and modulation of Fcγ receptors on human dendritic cells for targeted immunotherapyAdam Boruchov, MD
Mesoporous silica nanoparticles as drug delivery vehicles in a PDGFB-driven murine high grade glioma modelMichelle Bradbury, MD, PhD
Construction and characterization of retroviral vectors encoding genes capable of generating both primary and efficient co-stimulatory signals to T cells for use in the adoptive immunotherapy of B cell malignanciesRenier Brentjens, MD, PhD
Development and characterization of novel inhibitors of JAK kinasesJacqueline Bromberg, MD, PhD
Induction of natural EGFR inhibitorsLuca Cartegni, PhD
Therapeutic modulation of alternative splicingLuca Cartegni, PhD
Overcoming CDK4/6 inhibitor resistanceSarat Chandarlapaty, MD, PhD
Therapeutic targeting of Gαq pathway in uveal melanomaYu Chen, PhD
Development of small molecule inhibitors of MCL-1 for cancer therapyEmily Cheng, PhD
Using Self-Assembling DisAssembling (SADA) Platform in Pretargeted Radioimmunotherapy and DNA Damage Repair Inhibitors to Enhance Immunogenic Cell DeathNai-Kong Cheung, MD, PhD
Dual specific human monoclonal antibody targeting IGF-I and IGF-II for treating cancer in childrenNai-Kong Cheung, MD, PhD
Multistep targeting of GD2 using DOTA hookNai-Kong Cheung, MD, PhD
Optimizing radioimmunotherapy delivered through cerebrospinal fluid: Testing affinity-matured scFv constructs in xenograft modelsNai-Kong Cheung, MD, PhD
Humanized antibody targeting CSPG4 on melanomaNai-Kong Cheung, MD, PhD
SADA DOTA-PRID and SADA DOTA-PRIT for incurable cancersNai-Kong Cheung, MD, PhD; Darren Veach, PhD
Therapeutic and diagnostic targeting of DLK1 in cancerPing Chi, MD, PhD
Development of the epichaperome inhibitor LSI-137Gabriela Chiosis, PhD
Novel compounds inhibiting Hsp90Gabriela Chiosis, PhD and Neal Rosen, MD, PhD
Development of novel Hsp70 ATPase activity modulatorsGabriela Chiosis, PhD
PU24FCl, a novel selective Hsp90 inhibitorGabriela Chiosis, PhD
Bcr-Abl substrates and inhibitorsBayard Clarkson, MD
Leptin receptor as a target to eradicate CML tumor initiating cellsBayard Clarkson, MD
Design of molecular glue degraders to selectively target ERK2 over ERK1Arvin Dar, PhD
Development of D-peptide inhibitors of oncogenic KRAS mutantsSamuel Danishefsky, PhD
Testing the immunogenicity of a new unimolecular hexavalent vaccine in combination with the novel synthetic saponin adjuvant SQS-1-0-5-5Samuel Danishefsky, PhD
Cell migration inhibition: synthesis and evaluation of migrastatin and analogues for the identification of a novel chemotherapeuticSamuel Danishefsky, PhD
Preparation of multiple drug reversal agent 5-N-acetyl-ardeemin and some active analoguesSamuel Danishefsky, PhD
Synthesis and evaluation of a novel unimolecular multiantigenic vaccine against breast cancerSamuel Danishefsky, PhD
Telomerase inhibition: Synthesis and evaluation of UCS1025A and analogues for the identification of a novel chemotherapeuticSamuel Danishefsky, PhD and Malcolm Moore, D.Phil.
Development of an AML-directed dual-targeted CAR T cellAnthony Daniyan, MD
Targeting DJ-1 for cancer therapyYael David, PhD
Synthesis of a multi-scaffold library for high-throughput screening for novel inhibitors of androgen receptor signalingChristine DiBlasi, PhD
Synthetic study on proteasome inhibitor salinosporamide AAtsushi Endo, PhD
Novel enhancement strategies for cancer DNA vaccines: Epitope optimization and fusion vectorsManuel Engelhorn, PhD
Development of reagents to antagonize ceramide-mediated raft clustering in vivoZvi Fuks, MD
High throughput screening of specific inhibitors for kinase suppressor of Ras1 (KSR1)Zvi Fuks, MD
ASMase gene therapy for radiosensitizationZvi Fuks, MD and Richard Kolesnick, MD
Preclinical development of anti-ceramide monoclonal antibodiesZvi Fuks, MD
Preclinical evaluation of KSR phosphorothioate antisense oligonucleotides in treating gf Ras-dependent human malignanciesZvi Fuks, MD and Richard Kolesnick, MD
The development of highly concise routes to epothilones in the context of the chemical synthesis of the promising antitumor agent 4-desmethyl-12,13-desoxyEpothilone BAna Gabarda Ortega, PhD
L1CAM targeting 1xx CAR T cells for advanced solid tumorsKaruna Ganesh, MD, PhD
Design of small molecules that trigger secretion of neoantigen: Chaperone complexesJonathan Goldberg, PhD
Mechanism of TEM8 in increasing CD8 T cell responsesPolly Gregor, PhD
ROS-activatable prodrug of DoxazolineJan Grimm, MD, PhD
Clinically approved nanoparticles as environmental-responsive self reporting drug delivery systemJan Grimm, MD, PhD
Multimodality theranostics of pancreas cancerJan Grimm, MD, PhD
Gene expression profiling to identify therapeutic targets in chronic lymphocytic leukemiaMark Heaney, MD, PhD
Targeted nanoformulation and delivery strategy to improve the utility of PROTACSDaniel Heller, PhD
Nanoscale bio-imagingDaniel Heller, PhD
ZIC1: Therapeutic target and predictor of outcome in adult male germ cell tumorsJane Houldsworth, PhD
Biodistribution and radiobiological effectiveness of 225Ac and 213Bi for alpha-particle radioimmunotherapyJohn Humm, PhD
Targeting isocitrate dehydrogenase mutations by enzyme hyperactivationAndrew Intlekofer, MD, PhD
Identification of chemical inhibitors of the ULK1 kinase complexXuejun Jiang, PhD and Derek Tan, PhD
Development of novel therapies for endometrial carcinomasXuejun Jiang, PhD; Neal Rosen, MD, PhD
Identification and characterization of small molecule inhibitors of Apaf-1/Cytochrome c-mediated apoptosisXuejun Jiang, PhD and Derek Tan, PhD
Targeting the PTEN ubiquitin ligase NEDD4 with a novel electrophilic fragment libraryXuejun Jiang, PhD and Derek Tan, PhD
A modular platform for cell specific macromolecular drug deliveryAlex Kentsis, MD, PhD
Chemical library screen for musashi inhibitorsMichael Kharas, PhD
Inhibition of MSI translation in MSI driven leukemiasMichael Kharas, PhD
Tunable peptidomimetic nanoconjugates for cancer gene controlAlex Kentsis, MD, PhD
IL10 blockade as a novel immunotherapy across solid cancersDanny Khalil, MD, PhD
Developing MUSASHI RNA binding protein inhibitors to target cancerMichael Kharas, PhD
Raman nanostar-triggered automated laser ablation deviceMoritz Kircher, MD, PhD and Ricardo Toledo-Crow, PhD
C16:0 ceramide nano-liposomes reverse multi-drug resistanceRichard Kolesnick, MD
Sphingolipid-based anti-angiogenic chemosensitizationRichard Kolesnick, MD
Acid sphingomyelinase is obligate for gemcitabine actionRichard Kolesnick, MD
Small animal imaging and spectroscopyJason Koutcher, MD PhD
Leveraging living drugs for tumor-targeted radiotherapySimone Krebs, MD
Pre-clinical development of a novel class of proteasome inhibitorsMarc Ladanyi, MD
Improved detection of abl, c-kit, src and PDGFRα expressing tumors using a combination of positron labeled EGFR tyrosine kinase inhibitors and “stealth” nanocarriersSteve Larson, MD
Ac-225 DOTA Proteus for Pre-targeted Radioimmunotherapy (PRIT) of solid tumorsSteven Larson, MD
Alpha and Beta Pre-targeted Radioimmunotherapy for Peritoneal CarcinomatosisSteven Larson, MD
Statins to Enhance Pretargeted Radioimmunotherapy of HER2-expressing Esophagogastric TumorsJason Lewis, PhD
Amplifying the efficacy of pretargeted radioimmunotherapy (PRIT) in pancreatic cancerJason Lewis, PhD
Radiosensitization of malignant gliomas by gene therapyGloria Li, PhD and Philip Gutin, MD
Targeted delivery of attenuated interleukin-15 for ILC1-mediated cancer immunotherapyMing Li, PhD
Targeting TGF-β signaling in CD4+ T cells for cancer immunotherapyMing Li, PhD
Development of lysosomal inhibitors for pancreatic cancer treatmentYueming Li, PhD
Development of the autophagy-lysosome pathway blockers for pancreatic cancer treatmentYueming Li, PhD
Development of sulfonamide γ-secretase inhibitors for cancer therapyYueming Li, PhD
Preclinical studies of sulfonamide γ-secretase inhibitors for cancer therapyYueming Li, PhD
γ-Secretase: Target validation and inhibitor developmentYueming Li, PhD
Target notch signal pathway in B-cell neoplasmYueming Li, PhD
Harnessing senolytic CAR T cell based therapies for the treatment of solid tumorsScott Lowe, PhD
Targeting p53-regulated metabolism for anti-leukemia therapyScott Lowe, PhD
Advancing CARM1 Inhibitors as Preclinical Candidates Against Metastatic Breast CancerMinkui Luo, PhD
Developing mechanism-based protein arginine methyltransferase inhibitors as anti-cancer reagentsMinkui Luo, PhD
Develop protein methyltransferase inhibitors as anti-cancer drugsMinkui Luo, PhD
High-throughput screening for SETMAR inhibitors: Develop protein methyltransferase inhibitors as anticancer drugsMinkui Luo, PhD
High throughput screening for SETMAR inhibitorsMinkui Luo, PhD
Synthesis of polyketide-like small molecule librariesDaniel Macks, PhD
Effect of histone deacetylase inhibitors on normal and transformed prostate cellsPaul Marks, PhD
Monitoring molecular biomarkers in human cancerPeter Maslak, MD
Targeting CDH5 and simultaneously treating PSMA-positive and PSMA-negative prostate cancer with alpha particle therapyMichael McDevitt, PhD
Camelid antibodies armed with alpha particles and directed at enzalutamide-treated prostate cancerMichael McDevitt, PhD
A self-assembling synthetic clot to specifically infarct tumor tissue in vivoMichael McDevitt, PhD
RNAi prophylaxis of chemotherapy-induced nephrotoxicityMichael McDevitt, PhD
Optimizing EGFR Blockade in Human GlioblastomaIngo Mellinghoff, MD
Evaluation of epothilone analogs, synthetic microtubule stabilizing agents with potent anti-myeloma and anti-ovarian cancer actionMalcolm Moore, D.Phil.
Murine tumor xenograft models for preclinical drug developmentMalcolm Moore, D.Phil.
Targeting activated ADAM17 for the treatment of epithelial ovarian cancerDimitar Nikolov, PhD
Function blocking antibodies against ADAM metalloproteases for inhibition of Eph, EGFR and Notch-dependent tumorigenesisDimitar Nikolov, PhD
Small-molecule inhibitors of Eph receptor signalingDimitar Nikolov, PhD
Single-chain anti-EphA2 antibodies for treatment of lymphoma and leukemiaDimitar Nikolov, PhD
Real time polymerase chain reaction (PCR) for clinical and correlative studiesStephen Nimer, MD
The role of arginine methyltransferases in the pathogenesis of myeloid malignanciesStephen Nimer, MD
DNA vaccines against breast cancer: Synergy through targeting both tumor cells and tumor stromaFrancesca Orlandi, PhD
Chemical synthesis in carbohydrate-based cancer vaccinesOuathek Ouerfelli, PhD
Overcoming acquired resistance to targeted therapy in lung cancerWilliam Pao, MD, PhD
Development of Gboxin, a benzimidazolium compound, as an antitumor reagentLuis Parada, PhD
Protein chip biology system for high-thoughput screeningGavril Pasternak MD, PhD
Sigma receptors: a novel anti-proliferative target for tumor therapyGavril Pasternak, MD, PhD
Structure activity of the sigma1 antagonist binding pocketGavril Pasternak, MD, PhD
Development of potent small molecule inhibitors of the cGAS-STING dsDNA-sensing immune pathwayDinshaw Patel, PhD
Development of small molecule inhibitors of METTL3-METTL14 RNA methyltransferase complex as drugs against acute myeloid leukemiaDinshaw Patel, PhD
T-cell precursors and allogeneic hematopoietic stem cell transplantMiguel Perales, MD
SKI-N69: A candidate radiosensitizerJohn Petrini, PhD
Modulation of DNA damage signaling pathwaysJohn Petrini, PhD
Targeted synthetic immunity for activating site specific anti-tumor innate immune responseNagavarakishore Pillarsetty, PhD
Site specific activation of γδ T cells for cancer immunotherapy applicationsNagavarakishore Pillarsetty, PhD
Targeted nuclear delivery of EGF-Auger emitting radioconjugates for cancer therapyNagavarakishore Pillarsetty, PhD
Tumor antigen-directed molecular imaging to strategize T-cell immunotherapyVladimir Ponomarev, MD, PhD
Evaluation of endothelial cell apoptosis in human cancer specimens in response to ionizing radiationElizabeth Poyner, MD, PhD
Novel structure derivatives of trehalose dimycolate as cancer vaccine adjuvantsVivek Rao, PhD
Imaging of the Peripheral Nervous SystemThomas Reiner, PhD
Preclinical Testing of Hedgehog Inhibitors in Pancreatic CancerMarilyn Resh, PhD
Identification of hedgehog palmitoylation inhibitorsMarilyn Resh, PhD
Efficacy testing of TDI-3410, a Hedgehog Acyltransferase inhibitor, in mouse models of lung, breast and pancreatic cancerMarilyn Resh, PhD
Development and in vivo evaluation of clinical retroviral vectors designed to express high levels of mutant HSV thymidine kinase to increase the safety of T lymphocyte infusionsIsabelle Riviere, PhD
Development of improved TORC1 inhibitor-based therapies for the treatment of breast cancer and other carcinomasNeal Rosen, MD, PhD; Daniel Heller
Development of improved TORC1 inhibitor-based therapies for the treatment of breast cancer and other carcinomasNeal Rosen, MD, PhD; Daniel Heller
Development of combined inhibition of ERK and PI3K/AKT signaling as a strategy for the treatment of mutant RAS-dependent tumorsNeal Rosen, MD, PhD
DLL3 radioimmunoconjugates for high-grade neuroendocrine tumor imaging and therapyCharles Rudin, MD, PhD
Design of combinatorial therapeuticsChris Sander, PhD
Preclinical development of the anti-androgen A52 for prostate cancer therapyCharles Sawyers, MD
Therapeutic self-assembling nanodevicesDavid Scheinberg, MD, PhD
Radiotherapy with targeted multivalent α-particle generatorsDavid Scheinberg, MD, PhD
Development of novel inhibitors of SCCROBhuvanesh Singh, MD
A novel class of peptidomimetic agents targeting tumor growth, angio-genesis, and metastasesFrancis Sirotnak, PhD and David Scheinberg, MD, PhD
Modulation of chemotherapy sensitivity by alterations in PTEN/AKT signalingDavid Solit, MD
Characterization of an RNA binding protein targeted by thalidomide analoguesDavid Spriggs, MD
MUC16 synthetic lethal screening in ovarian cancerDavid Spriggs, MD
Development of novel menin inhibitors for glioma therapyViviane Tabar, MD
pdfSEAKER: Development of CAR T cells that express human peptide deformylase (hsPDF) to activate synergistic small-molecule prodrugs locally at tumorsDerek Tan, PhD
onSEAKER: Engineering CAR T cells to biosynthesize synergistic small molecule drugs in situDerek Tan, PhD
Targeted delivery of epigenetic small-molecule drugs by SEAKER cellsDerek Tan, PhD
A novel CAR T-cell platform for targeted, local biosynthesis of small-molecule therapeuticsDerek Tan, PhD
Studying Chk1-mediated signaling pathways using chemical genetics and functional imagingArchie N. Tse, MD, PhD
Identification of novel small molecules with anti-proliferative action towards human lung cancer cell lines harboring oncogenic EGFR or KRASHarold Varmus, MD
ESSENCE compounds as tools for specific modulation of alternative splicing patternsSandra Vorlova, PhD
The oncogenic action of NRF2 depends on de-glycation by Fructosamine-3-kinaseHans-Guido Wendel, MD
Defining the mechanism underlying GITR agonist activityJedd Wolchok, MD, PhD
TMC-95A analogues as potential antitumor agentsZhi-Qiang Yang, PhD
Controlled rate freezer for preclinical laboratory studiesJames Young, MD
Janus kinase 2 (JAK2) as a therapeutic target in graft-versus-host diseaseJames Young, MD and Brian Betts, MD
Reversal of indoleamine 2,3-dioxygenase (IDO)-mediated suppression of tumor immunity stimulated by human dendritic cellsJames Young, MD